StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
VYGRVoyager Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$1.84▲ 5.75%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $111.2MShares out 60.4M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

4
  • 4d agoPre-market26.10.21 21:07
    8-KKey event#●●●

    Voyager Therapeutics, Inc.

    Voyager Therapeutics has appointed Chief Operating Officer Robin Swartz as the new President, effective immediately. Swartz is expected to succeed current CEO Alfred W. Sandrock, Jr. following the receipt of initial clinical trial data for VY1706 in the first quarter of 2027.…more

    $1.84+5.75%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 8.6After-hours26.08.07 05:03
    8-KKey event

    Voyager Therapeutics, Inc.

    보이저 테라퓨틱스는 2026년 2분기 매출 316만 달러, 순손실 2,447만 달러(주당순손실 0.40달러)를 기록했습니다. 6월 30일 기준 현금 및 현금성 자산은 1억 4,881만 달러로 2028년까지 운영 자금을 확보했으며, 알츠하이머 치료제 후보물질 VY7523과 VY1706의 임상 데이터를 2026년 4분기에 발표할 예정입니다.…more

    $1.84+5.75%vs prev close
    View filingShare
  • 8.6After-hours26.08.07 05:01
    10-QEarnings

    Voyager Therapeutics, Inc.

    보이저 테라퓨틱스는 2026년 2분기 실적 보고와 함께 정관 개정을 통해 발행 가능한 총 주식 수를 기존 1억 2,500만 주에서 2억 4,500만 주로 확대했습니다. 또한 2026년 4분기에 알츠하이머 치료제 후보물질 VY7523의 임상 1상 데이터 생성 및 VY1706의 임상 시험 개시를 계획하고 있습니다.…more

    $1.84+5.75%vs prev close
    View filingShare

3 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 4d agoPre-market26.10.21 21:01
    #●●●#●●●

    Voyager Therapeutics Announces CEO Succession Plan and Appoints Robin Swartz as President…more

    Voyager Therapeutics has appointed current COO Robin Swartz as President, with plans for her to succeed CEO Dr. Alfred Sandrock in Q1 2027. Dr. Sandrock will transition to the Board of Directors following the release of initial safety data for the company's lead gene therapy candidate.…more

    $1.84+5.75%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 8.6After-hours26.08.07 05:01

    ●●●●●●●● ●●●●● ●●●●●●

    보이저 테라퓨틱스는 2분기 실적 발표와 함께 알츠하이머 치료제 후보물질들의 임상 진전 상황을 공개했습니다. 현재 보유 현금으로 2028년까지 운영이 가능하며, 연내 주요 임상 데이터 확보를 목표로 하고 있습니다.…more

    $1.84+5.75%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →